The Competition Commission has decided not to prosecute a complaint of alleged anticompetitive conduct that was initiated against pharmaceuticals group Johnson & Johnson and its subsidiary Janssen Pharmaceutica.
The commission investigated allegations of abuse of dominance against Johnson & Johnson and its subsidiary after the companies had filed a secondary patent for Bedaquiline (trading as Sirturo), a drug used in the treatment of tuberculosis (TB), effectively restricting the entry of generic alternatives.
